Bright Peak Therapeutics

Versant-backed Bright Peak sets a date to bring its IL-2 into the clinic — but all eyes are on an IPO after latest mega-round drops
Endpoints
Thu, 06/10/21 - 11:08 am
Bright Peak Therapeutics
Versant
IPOs
funding
cytokines
A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer
Endpoints
Tue, 07/28/20 - 11:06 am
protein engineering
Bright Peak Therapeutics
Versant Ventures